The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT06211062
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME/CFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are: how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (GI) inflammation and normalize the GI and systemic/brain interface? how well is it working on IBS severity?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- ME/CFS
- IBS - Irritable Bowel Syndrome
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 45 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Nova Southeastern University
- Last updated on ClinicalTrials.gov
- March 4, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Institute for Neuroimmune Medicine · Fort Lauderdale, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.